Castle Biosciences Announces Support for OHSU’s War on Melanoma™
Castle Biosciences (CSTL) has partnered with Oregon Health & Science University in the War on Melanoma, a public health initiative aimed at early detection and prevention of melanoma. This collaboration supports education and awareness programs, including the Start Seeing Melanoma campaign and the Skin Crew, which involves professionals identifying potential skin cancer signs. Castle emphasizes the importance of early diagnosis in improving patient outcomes. The company continues to focus on innovative tests to enhance patient care and disease management.
- Collaboration with OHSU enhances brand visibility and credibility.
- Supports public health initiatives aimed at early melanoma detection.
- Alignment with innovative diagnostic services can lead to increased patient engagement.
- None.
“Our goal is to prevent melanoma, and if we can’t prevent it, then we need to catch it as early as possible,” said
The War on Melanoma is engaging the statewide community in
- The Start Seeing Melanoma campaign is raising awareness of the importance of personal skin checks to identify melanoma early, focused on the premise that “melanoma stands out.”
-
The Skin Crew is enlisting the assistance of licensed skin, hair and personal health professionals, such as estheticians, massage therapists, tattoo artists and hair stylists, to be on the lookout for suspicious moles on their clients.
Skin Crew members can use a medical grade dermatoscope attachment for their phone, called a Sklip™, with a limited supply of free devices for members inOregon . Once paired with the Sklip app, anyone can upload images anonymously and get an affordable assessment from a dermatologist within 24 hours on whether a mole requires additional follow-up.
“At Castle, we are focused on improving the lives of patients with skin cancer and understand that awareness and the early diagnosis of melanoma, along with innovations in prognostic testing, are critical for improving health outcomes,” said
About
Castle’s current portfolio consists of tests for skin cancers, uveal melanoma, Barrett’s esophagus and mental health conditions. Additionally, the Company has active research and development programs for tests in other diseases with high clinical need, including its test in development to predict systemic therapy response in patients with moderate-to-severe psoriasis, atopic dermatitis and related conditions. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, Twitter and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, DecisionDx-SCC, myPath Melanoma, DecisionDx DiffDx-Melanoma, DecisionDx-UM, DecisionDx-PRAME, DecisionDx-UMSeq, TissueCypher and IDgenetix are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220620005087/en/
Investor Contact:
czuckero@castlebiosciences.com
Media Contact:
amarshall@castlebiosciences.com
Source:
FAQ
What is the collaboration between Castle Biosciences and OHSU about?
How does the War on Melanoma aim to prevent skin cancer?
What role does Castle Biosciences play in the War on Melanoma?